Evidence map›Paper›PMID 30402498›Full record

ReviewBioMed research international2018

Onco-Multi-OMICS Approach: A New Frontier in Cancer Research.

Sajib Chakraborty, Md Ismail Hosen, Musaddeque Ahmed, Hossain Uddin Shekhar

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06108310 (ATTRACT - ArTificial inTelligence-based RAdiogenomics in Colon Tumors), which is not on this map. Cited by 172 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
172citing papers in PubMed, 2 pooled it
8.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06108310 unknown statusnot on this mapstarted 2021, after this paper: background citation

ATTRACT - ArTificial inTelligence-based RAdiogenomics in Colon Tumors

TypeobservationalSponsorUniversity of Roma La SapienzaRan2021 to 2025Enrolled500ConditionsColon Cancer Stage II, Colon Cancer Stage III
3 · Its place in the literature

Who cites it

172 citing papers in PubMed, 2 syntheses or guidelines pooled it, 319 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Target identification and assessment in the era of AI.Nature reviews. Drug discovery · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. AI based multiomics integration for cancer diagnosis and prognosis.Journal, genetic engineering & biotechnology · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

112 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Sajib ChakrabortyDepartment of Biochemistry and Molecular Biology, University of Dhaka, Dhaka 1000, Bangladesh.ORCID 0000-0002-8900-503X
Md Ismail HosenDepartment of Biochemistry and Molecular Biology, University of Dhaka, Dhaka 1000, Bangladesh.ORCID 0000-0003-0862-7206
Musaddeque AhmedPrincess Margaret Cancer Centre/University Health Network, Toronto, Ontario, Canada.
Hossain Uddin ShekharDepartment of Biochemistry and Molecular Biology, University of Dhaka, Dhaka 1000, Bangladesh.ORCID 0000-0002-5947-330X
University of Dhaka · BDUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The acquisition of cancer hallmarks requires molecular alterations at multiple levels including genome, epigenome, transcriptome, proteome, and metabolome. In the past decade, numerous attempts have been made to untangle the molecular mechanisms of carcinogenesis involving single OMICS approaches such as scanning the genome for cancer-specific mutations and identifying altered epigenetic-landscapes within cancer cells or by exploring the differential expression of mRNA and protein through transcriptomics and proteomics techniques, respectively. While these single-level OMICS approaches have contributed towards the identification of cancer-specific mutations, epigenetic alterations, and molecular subtyping of tumors based on gene/protein-expression, they lack the resolving-power to establish the casual relationship between molecular signatures and the phenotypic manifestation of cancer hallmarks. In contrast, the multi-OMICS approaches involving the interrogation of the cancer cells/tissues in multiple dimensions have the potential to uncover the intricate molecular mechanism underlying different phenotypic manifestations of cancer hallmarks such as metastasis and angiogenesis. Moreover, multi-OMICS approaches can be used to dissect the cellular response to chemo- or immunotherapy as well as discover molecular candidates with diagnostic/prognostic value. In this review, we focused on the applications of different multi-OMICS approaches in the field of cancer research and discussed how these approaches are shaping the field of personalized oncomedicine. We have highlighted pioneering studies from "The Cancer Genome Atlas (TCGA)" consortium encompassing integrated OMICS analysis of over 11,000 tumors from 33 most prevalent forms of cancer. Accumulation of huge cancer-specific multi-OMICS data in repositories like TCGA provides a unique opportunity for the systems biology approach to tackle the complexity of cancer cells through the unification of experimental data and computational/mathematical models. In future, systems biology based approach is likely to predict the phenotypic changes of cancer cells upon chemo-/immunotherapy treatment. This review is sought to encourage investigators to bring these different approaches together for interrogating cancer at molecular, cellular, and systems levels.

Indexed as

AnimalsBiomedical ResearchGenomicsHumansMetabolomicsNeoplasms

Identifiers

PMID30402498
PMCPMC6192166
OpenAlexW2895654791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.